Francis X McCormack, MD
University of Cincinnati · University of Cincinnati Medical Center Division of Pulmonary and Critical Care Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Francis X McCormack, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02737202 · Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisBaylor College of Medicine · terminated · Pulmonary Lymphangioleiomyomatosis · principal investigator
- N/ANCT02432560 · Safety and Durability of Sirolimus for Treatment of LAMUniversity of Cincinnati · recruiting · Lymphangioleiomyomatosis · study director
- Ph2NCT01353209 · Letrozole for LymphangioleiomyomatosisUniversity of Cincinnati · completed · Lymphangioleiomyomatosis · principal investigator
- Ph3NCT00414648 · Efficacy and Safety of Sirolimus in LAMUniversity of Cincinnati · completed · Lymphangioleiomyomatosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Therapeutic Strategy for LAM (Lymphangioleiomyomatosis)UH3TR000961 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI N. Tony Eissa · fiscal years 2014 to 2016Named on NCT02737202
- RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung DiseasesU54HL127672 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Bruce C Trapnell · fiscal years 2014 to 2018Named on NCT02432560
- Rare Lung Disease Clinical Research NetworkU54RR019498 · NCRR · CINCINNATI CHILDRENS HOSP MED CTR · PI Bruce C Trapnell · fiscal years 2003 to 2008Named on NCT00414648
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.